PL2773331T3 - Preparaty do leczenia cukrzycy - Google Patents
Preparaty do leczenia cukrzycyInfo
- Publication number
- PL2773331T3 PL2773331T3 PL12798470T PL12798470T PL2773331T3 PL 2773331 T3 PL2773331 T3 PL 2773331T3 PL 12798470 T PL12798470 T PL 12798470T PL 12798470 T PL12798470 T PL 12798470T PL 2773331 T3 PL2773331 T3 PL 2773331T3
- Authority
- PL
- Poland
- Prior art keywords
- diabetes
- formulations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553388P | 2011-10-31 | 2011-10-31 | |
| US201261609123P | 2012-03-09 | 2012-03-09 | |
| EP12798470.6A EP2773331B1 (en) | 2011-10-31 | 2012-10-31 | Formulations for the treatment of diabetes |
| PCT/US2012/062816 WO2013067022A1 (en) | 2011-10-31 | 2012-10-31 | Formulations for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2773331T3 true PL2773331T3 (pl) | 2016-08-31 |
Family
ID=47324375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12798470T PL2773331T3 (pl) | 2011-10-31 | 2012-10-31 | Preparaty do leczenia cukrzycy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9138479B2 (pl) |
| EP (1) | EP2773331B1 (pl) |
| JP (1) | JP6117811B2 (pl) |
| KR (1) | KR102007057B1 (pl) |
| CN (1) | CN103930096B (pl) |
| AU (1) | AU2012332556B2 (pl) |
| BR (1) | BR112014010275A2 (pl) |
| CA (1) | CA2853942C (pl) |
| DK (1) | DK2773331T3 (pl) |
| EA (1) | EA027744B1 (pl) |
| ES (1) | ES2574761T3 (pl) |
| MX (1) | MX349383B (pl) |
| PL (1) | PL2773331T3 (pl) |
| SG (1) | SG11201401921YA (pl) |
| WO (1) | WO2013067022A1 (pl) |
| ZA (1) | ZA201403795B (pl) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX342675B (es) * | 2011-03-10 | 2016-10-07 | Xeris Pharmaceuticals Inc | Formulaciones estables para inyeccion parenteral de farmacos de peptido. |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| MX360420B (es) * | 2012-12-19 | 2018-10-31 | Wockhardt Ltd | Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| US20170007675A1 (en) * | 2014-02-06 | 2017-01-12 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations and methods for preparation |
| WO2015153728A1 (en) | 2014-04-02 | 2015-10-08 | Xeris Pharmaceuticals, Inc. | Polar aprotic solvent-compatible infusion sets, components, and methods |
| KR102428675B1 (ko) | 2014-08-06 | 2022-08-02 | 엑스에리스 파머수티클스, 인크. | 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법 |
| US9649364B2 (en) * | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| WO2016196976A1 (en) * | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| EP3307295A1 (en) * | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| AU2017334290B2 (en) * | 2016-09-29 | 2023-04-20 | Arecor Limited | Novel formulations |
| US10914728B2 (en) * | 2016-10-24 | 2021-02-09 | Novo Nordisk A/S | Bioassay for insulin formulations |
| CN106310232A (zh) * | 2016-10-25 | 2017-01-11 | 南京师范大学 | 一种稳定的胰岛素解聚体超分子复合物及其制备方法 |
| WO2018122278A1 (fr) | 2016-12-27 | 2018-07-05 | Adocia | Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| EP4290320B8 (en) | 2017-05-05 | 2026-03-04 | mylife Diabetes Care AG | Closed loop control of physiological glucose |
| ES2982668T3 (es) | 2017-06-02 | 2024-10-17 | Xeris Pharmaceuticals Inc | Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación |
| KR102757948B1 (ko) * | 2017-07-27 | 2025-01-23 | 아도시아 | 적어도 사람 인슐린 a21g 및 식사 작용 글루카곤 억제제를 포함하는 주사가능한 수용액 형태의 조성물 |
| FR3082426A1 (fr) | 2018-06-14 | 2019-12-20 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale |
| FR3083085B1 (fr) | 2018-06-29 | 2020-10-02 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| FR3083086A1 (fr) | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| KR20240171194A (ko) | 2017-12-07 | 2024-12-06 | 아도시아 | 아밀린, 아밀린 작용제 수용체 또는 아밀린 유사체 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물 |
| WO2019110797A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| CN111683674A (zh) | 2017-12-07 | 2020-09-18 | 阿道恰公司 | 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物 |
| WO2019115411A1 (fr) | 2017-12-07 | 2019-06-20 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| WO2019125932A1 (en) | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Closed loop control of physiological glucose |
| CN112313754A (zh) * | 2018-06-22 | 2021-02-02 | 伊莱利利公司 | 胰岛素和普兰林肽输送系统、方法和设备 |
| FR3084586B1 (fr) | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
| US11439606B2 (en) * | 2018-12-03 | 2022-09-13 | Guadalupe Cleva Villanueva Lopez | Reduction of hyperglycemia by administration of dimethylformamide for treating hyperglycemic conditions, including diabetes mellitus |
| CN113661006A (zh) | 2019-02-05 | 2021-11-16 | 林迪生物科学公司 | 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法 |
| WO2020168003A1 (en) * | 2019-02-12 | 2020-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Co-formulations of amylin analogues with insulin analogues for treatment of diabetes |
| MX2021014614A (es) * | 2019-05-31 | 2022-01-06 | Xeris Pharmaceuticals Inc | Composiciones terapeuticas estables en solventes polares aproticos y metodos de elaboracion de las mismas. |
| WO2021119607A1 (en) * | 2019-12-13 | 2021-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016895A (en) | 1958-08-01 | 1962-01-16 | Pan American Lab Inc | Injector for subcutaneous implantation of solids |
| US5260306A (en) | 1981-07-24 | 1993-11-09 | Fisons Plc | Inhalation pharmaceuticals |
| GB2119248A (en) * | 1982-04-28 | 1983-11-16 | John Kenneth Mcmullen | Insulin formulations and method of producing them |
| CH664005A5 (de) | 1984-05-19 | 1988-01-29 | Glatt Maschinen & Apparatebau | Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens. |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4848094A (en) | 1988-04-29 | 1989-07-18 | Union Carbide Corporation | Droplet freezing method and apparatus |
| US5031336A (en) | 1989-08-31 | 1991-07-16 | Abbott Laboratories | Lyophilization of bulk pharmaceuticals |
| US5092843A (en) | 1990-04-12 | 1992-03-03 | Survival Technology, Inc. | Dispersion multichamber auto-injector |
| AU7908791A (en) | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
| US5208998A (en) | 1991-02-25 | 1993-05-11 | Oyler Jr James R | Liquid substances freeze-drying systems and methods |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| RU2147226C1 (ru) | 1994-09-29 | 2000-04-10 | Квадрант Хэлткэа (Ю Кей) Лимитед | Высушенные распылением микрочастицы как терапевтические носители |
| US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US5945128A (en) | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| IN184589B (pl) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| ES2256898T3 (es) | 1996-12-20 | 2006-07-16 | Alza Corporation | Composicion de gel y procedimientos. |
| JP2001507701A (ja) | 1996-12-31 | 2001-06-12 | インヘイル・セラピューティック・システムズ・インコーポレーテッド | 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物 |
| ZA984697B (en) * | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
| DE69736140T2 (de) | 1997-11-18 | 2007-04-19 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten |
| FR2783433B1 (fr) | 1998-09-18 | 2001-02-16 | Delab | Seringues pour l'administration de formulations pateuses ou semi-solides |
| SE9803662D0 (sv) | 1998-10-26 | 1998-10-26 | Pharmacia & Upjohn Ab | Autoinjector |
| US6199297B1 (en) | 1999-02-01 | 2001-03-13 | Integrated Biosystems, Inc. | Lyophilization apparatus and methods |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US6253463B1 (en) | 1999-04-26 | 2001-07-03 | Niro A/S | Method of spray drying |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| FR2801226B1 (fr) * | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
| US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
| AU4477001A (en) | 2000-04-18 | 2001-10-30 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| AU2001245346A1 (en) | 2000-06-28 | 2002-01-08 | Atul J. Shukla | Biodegradable vehicles and delivery systems of biologically active substances |
| US7396841B2 (en) | 2000-08-18 | 2008-07-08 | Takeda Pharmaceutical Company Limited | Injections |
| FR2814951B1 (fr) * | 2000-10-06 | 2003-01-17 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation |
| RO120121B1 (ro) | 2000-12-18 | 2005-09-30 | Elena Ionaşcu | Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| US7314636B2 (en) | 2001-06-29 | 2008-01-01 | Medgraft Microtech, Inc. | Biodegradable injectable implants containing glycolic acid |
| EP1413310A1 (en) | 2001-07-09 | 2004-04-28 | Yamanouchi Pharmaceutical Co. Ltd. | Sustained-release compositions for injection and process for producing the same |
| US6733813B2 (en) | 2001-08-02 | 2004-05-11 | Ocean Spray Cranberries, Inc. | Process for producing acids-enriched juice and acids-reduced juice |
| WO2003041684A2 (en) | 2001-11-14 | 2003-05-22 | Alza Corporation | Injectable depot compositions and uses thereof |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US20050203175A1 (en) | 2001-12-18 | 2005-09-15 | Ioulia Tseti | Parenteral composition of paracetamol |
| CN1171610C (zh) | 2002-04-23 | 2004-10-20 | 张瑞香 | 一种治疗心脑血管和眼底病的中药针剂及其制备方法 |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| EP1558234B1 (en) | 2002-10-25 | 2007-05-23 | Dompé S.P.A. | Painless injectable compositions containing salt of 2-arylpropionic acids |
| AU2003299691B2 (en) | 2002-12-18 | 2008-06-05 | Algorx Pharmaceuticals, Inc. | Administration of capsaicinoids |
| EP3597262B1 (en) | 2002-12-20 | 2023-12-27 | Xeris Pharmaceuticals, Inc. | Formulation for intracutaneous injection |
| WO2004098643A1 (en) | 2003-04-14 | 2004-11-18 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| PT1468697E (pt) | 2003-04-14 | 2008-03-05 | Wyeth Corp | Composições contendo piperacilina e tazobactam úteis para injecção |
| KR100517643B1 (ko) | 2003-07-25 | 2005-09-28 | 한국과학기술연구원 | 온도 감응성 폴리포스파젠계 고분자, 이의 제조방법 및이를 이용한 주입형 온도 감응성 폴리포스파젠 하이드로젤 |
| DK1502589T3 (da) | 2003-07-31 | 2006-09-25 | Emdoka Bvba Drug Registration | Veterinære, vandige injicerbare suspensioner indeholdende florfenicol |
| US20050100538A1 (en) | 2003-07-31 | 2005-05-12 | Attawia Mohamed | Intradiscal injection of anti-oxidants |
| WO2004057939A2 (en) | 2003-08-22 | 2004-07-15 | Unaxis Balzers Aktiengesellschaft | Method for the bonding of disk-shaped substrates and apparatus for carrying out the method |
| BRPI0414907A (pt) | 2003-09-30 | 2006-11-07 | Acusphere Inc | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas |
| ATE381945T1 (de) | 2004-03-12 | 2008-01-15 | Intercell Ag | Verfahren zur solubilisierung von peptid- mischungen |
| US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| US20060160823A1 (en) | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| AU2005284714A1 (en) | 2004-09-13 | 2006-03-23 | Pr Pharmaceuticals, Inc. | Long acting injectable crystal formulations of estradiol metabolites and methods of using same |
| JP5069130B2 (ja) | 2005-01-27 | 2012-11-07 | エリモス・ファーマスーティカルズ・エルエルシー | Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤 |
| US20080200383A1 (en) | 2005-04-08 | 2008-08-21 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent |
| US20080305161A1 (en) | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| MX2008009125A (es) | 2006-01-18 | 2008-10-23 | Qps Llc | Composiciones farmaceuticas con estabilidad mejorada. |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| CA2653200A1 (en) | 2006-05-25 | 2007-12-06 | The General Hospital Corporation | Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations |
| AU2007293068C1 (en) | 2006-09-07 | 2013-09-19 | Boehringer Ingelheim Animal Health USA Inc. | Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations |
| US20100015195A1 (en) | 2006-10-05 | 2010-01-21 | Rajesh Jain | Injectable depot compositions and it's process of preparation |
| WO2008098212A2 (en) | 2007-02-08 | 2008-08-14 | Diobex, Inc. | Extended release formulations of glucagon and other peptides and proteins |
| ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
| ES2563038T3 (es) | 2007-04-30 | 2016-03-10 | Novo Nordisk A/S | Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca |
| JP2010525033A (ja) * | 2007-04-30 | 2010-07-22 | ノボ・ノルデイスク・エー／エス | 高濃縮のインスリン溶液及び組成物 |
| US8946208B2 (en) | 2007-08-31 | 2015-02-03 | Archimedes Development Limited | Non-aqueous pharmaceutical composition |
| US20090088393A1 (en) | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| WO2009060473A2 (en) | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Injectable compositions, processes and uses thereof |
| EP2060268A1 (en) * | 2007-11-15 | 2009-05-20 | Novo Nordisk A/S | Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| EA201070656A1 (ru) | 2007-11-28 | 2010-12-30 | Тева Фармасьютикал Индастриз, Лтд. | Способ задержки начала проявления клинически определенного рассеянного склероза |
| BRPI0907186A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Gmbh & Co Kg | Composições proteicas pulverizadas e métodos para sua produção |
| MX2011000795A (es) | 2008-07-23 | 2011-03-29 | Bharat Serums & Vaccines Ltd | Nanoemulsion estable inyectable de docetaxel de aceite en agua. |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
| MX342675B (es) * | 2011-03-10 | 2016-10-07 | Xeris Pharmaceuticals Inc | Formulaciones estables para inyeccion parenteral de farmacos de peptido. |
-
2012
- 2012-10-31 PL PL12798470T patent/PL2773331T3/pl unknown
- 2012-10-31 EP EP12798470.6A patent/EP2773331B1/en active Active
- 2012-10-31 BR BR112014010275A patent/BR112014010275A2/pt not_active IP Right Cessation
- 2012-10-31 KR KR1020147014882A patent/KR102007057B1/ko active Active
- 2012-10-31 CA CA2853942A patent/CA2853942C/en active Active
- 2012-10-31 ES ES12798470.6T patent/ES2574761T3/es active Active
- 2012-10-31 US US14/354,848 patent/US9138479B2/en active Active
- 2012-10-31 AU AU2012332556A patent/AU2012332556B2/en active Active
- 2012-10-31 WO PCT/US2012/062816 patent/WO2013067022A1/en not_active Ceased
- 2012-10-31 EA EA201490913A patent/EA027744B1/ru not_active IP Right Cessation
- 2012-10-31 MX MX2014005311A patent/MX349383B/es active IP Right Grant
- 2012-10-31 CN CN201280053399.9A patent/CN103930096B/zh active Active
- 2012-10-31 JP JP2014539160A patent/JP6117811B2/ja active Active
- 2012-10-31 DK DK12798470.6T patent/DK2773331T3/en active
- 2012-10-31 SG SG11201401921YA patent/SG11201401921YA/en unknown
-
2014
- 2014-05-23 ZA ZA2014/03795A patent/ZA201403795B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA027744B1 (ru) | 2017-08-31 |
| ES2574761T3 (es) | 2016-06-21 |
| EA201490913A1 (ru) | 2014-09-30 |
| JP6117811B2 (ja) | 2017-04-19 |
| JP2014532667A (ja) | 2014-12-08 |
| US9138479B2 (en) | 2015-09-22 |
| KR20140107228A (ko) | 2014-09-04 |
| AU2012332556A1 (en) | 2014-06-19 |
| KR102007057B1 (ko) | 2019-08-02 |
| CA2853942A1 (en) | 2013-05-10 |
| BR112014010275A2 (pt) | 2017-04-18 |
| ZA201403795B (en) | 2016-01-27 |
| CN103930096A (zh) | 2014-07-16 |
| WO2013067022A1 (en) | 2013-05-10 |
| AU2012332556B2 (en) | 2016-05-26 |
| SG11201401921YA (en) | 2014-05-29 |
| EP2773331A1 (en) | 2014-09-10 |
| DK2773331T3 (en) | 2016-03-14 |
| CA2853942C (en) | 2020-08-25 |
| MX2014005311A (es) | 2014-10-06 |
| MX349383B (es) | 2017-07-26 |
| US20140349926A1 (en) | 2014-11-27 |
| CN103930096B (zh) | 2017-05-31 |
| EP2773331B1 (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| IL232251A0 (en) | Protocol for the treatment of type 2 diabetes | |
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| IL223289A0 (en) | Treatment of type 2 diabetes | |
| IL232239A0 (en) | Medical use | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
| ZA201308117B (en) | Avian-based treatment | |
| IL228589A0 (en) | Medical Care | |
| GB201102283D0 (en) | Treatment | |
| IL232294A0 (en) | Preparations for the treatment of diabetes | |
| GB201106981D0 (en) | Compounds for the treatment of clostridium difficle-associated disease | |
| GB201110659D0 (en) | composition for skin treatment | |
| GB201110653D0 (en) | Composition for skin treatment | |
| AP2015008270A0 (en) | Preparation for the treatment of tuberculosis | |
| GB201119533D0 (en) | Compounds for the treatment of neoplasia | |
| GB201102263D0 (en) | Treatment | |
| GB201102265D0 (en) | Treatment | |
| GB201102276D0 (en) | Treatment | |
| GB201102277D0 (en) | Treatment | |
| GB201102274D0 (en) | Treatment | |
| GB201102284D0 (en) | Treatment | |
| GB201102288D0 (en) | Treatment |